🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jacqueline Vuky

Oregon Health & Science University

ORCID: 0000-0001-5795-3361

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 7 papers. Top paper: “Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer”.

Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

Journal of Clinical Oncology(2020)10.1200/jco.19.01213

N/A

4.9DataRank · unranked

294 citations

Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell, Petros Grivas, Joaquim Bellmunt +11 more

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Nature Medicine(2022)10.1038/s41591-022-01931-y

N/A

3.9DataRank · unranked

240 citations

Philippe A. Cassier, Salvatore Siena, Elena Garralda, Luis Paz‐Ares, Pilar Garrido +14 more

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

Annals of Oncology(2022)10.1016/j.annonc.2022.11.012

N/A

3.4DataRank · unranked

116 citations

Daniel Castellano, Petros Grivas, David J. Vaughn, Thomas Powles, Jacqueline Vuky +15 more

Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies

npj Precision Oncology(2021)10.1038/s41698-021-00232-w

N/A

0.953DataRank · unranked

27 citations

Allen Li, Allison Creason, Courtney B. Betts, Jamie M. Keck, Brett Johnson +23 more

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3089

N/A

0.587DataRank · unranked

49 citations

Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae‐Lyun Lee +26 more

Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational PARP inhibitor therapy combinations

medRxiv(2020)10.1101/2020.07.25.20146431

N/A

0.208DataRank · unranked

3 citations

Allen Li, Allison Creason, Courtney B. Betts, Jamie M. Keck, Brett Johnson +23 more

1752P Post hoc analysis of pembrolizumab efficacy in potentially platinum ineligible patients with urothelial carcinoma enrolled in KEYNOTE-052 and LEAP-011

Annals of Oncology(2022)10.1016/j.annonc.2022.07.1830

N/A

0.104DataRank · unranked

1 citations

T. Csoszi, N. Matsubara, Su‐Jin Shin, S.H. Park, Vagif Atduev +15 more